Brief: Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Decoy Therapeutics

07/11/2023 13:38

Nov 7 (Reuters) - Salarius Pharmaceuticals Inc  SLRX.O :
    * SALARIUS COMPLETES FDA TYPE B MEETING FOR SECLIDEMSTAT
EWING
SARCOMA DEVELOPMENT PROGRAM
    * SALARIUS PHARMACEUTICALS INC - FUTURE DEVELOPMENT
ACTIVITIES
WERE IDENTIFIED
    * SALARIUS PHARMACEUTICALS INC - INTENDS TO SUBMIT AN
AMENDED
EWING SARCOMA CLINICAL TRIAL PROTOCOL

Source text for Eikon:  ID:nGNX4yMG0y 
Further company coverage:  SLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))